Nigel Stevenson, PhD

Dr. Stevenson obtained his Ph.D. at the University of London, UK in 1983 in Nuclear Physics. He then worked as a research scientist at TRIUMF, the Canadian national accelerator facility, where he went on to head up the Isotope Production group. Subsequently, he has held several commercial positions including: V.P. of Isotope Production and Research for Theragenics Corporation, COO of Trace Life Sciences and COO of Clear Vascular, Inc. Starting in 2015, Dr. Stevenson served as the Chief Operating Officer of Serene, LLC – a company that is exploring the treatment of rheumatological and other medical conditions with radioactive products. In 2019 a new commercial veterinary company, Exubrion Therapeutics, was formed to treat canine osteoarthritis and Dr. Stevenson serves as the Chief Operations Officer. Dr. Stevenson has organized several isotope conferences over the years including the 3rd International Conference on Isotopes held in Vancouver in September 1999 where he served as the Conference Chairperson. He has also had various roles in the International Isotope Society including that of the President of the Canadian Chapter and past President of the World Council on Isotopes.